Effect of trimetazidine MR 35 mg on the emergence of choroidal neovascularisation in age-related macular degeneratio
Not Applicable
Completed
- Conditions
- Aged-related macular degenerationEye DiseasesOther retinal disorders
- Registration Number
- ISRCTN99532788
- Lead Sponsor
- Institut de Recherches Internationales Servier (France)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 1100
Inclusion Criteria
1. Male and female
2. Caucasian
3. Aged 55 to 83 years with age-related macular degeneration
4. Neovascularisation on the first eye
Exclusion Criteria
1. Cataract
2. Diabetic retinopathy
3. Optical neuropathy
4. Neovascularisation on the studied eye
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Effect on choroidal neovascularisation evaluated each year.
- Secondary Outcome Measures
Name Time Method 1. Effect of the serous drusen evaluated each year<br>2. Evaluation of pigment epithelium lesion evaluated each year<br>3. Clinical acceptability of trimetazidine evaluated each 6 months